Key clinical point: A retrospective study revealed similar outcomes among patients with early stage follicular lymphoma, regardless of the treatment they received.
Major finding: There was no significant difference in overall survival between patients who received active treatment and those who were managed with watchful waiting (P = .90).
Study details: A retrospective study of 365 patients with newly diagnosed, stage I/II follicular lymphoma.
Disclosures: The researchers reported relationships with many pharmaceutical companies.
Tobin JWD et al. Blood Adv. 2019 Oct 8;3(19):2804-11.